Business
GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More
GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More\nCanada NewsWire\nLAS VEGAS, Feb. 5, 2018\n\n\n\nLAS VEGAS, Feb. 5, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) has filed a nonprovisional patent application to protect its cannabinoid-containing complex mixtures for the treatment of inflammatory disorders. The new patent application claims the benefit of GB Sciences' provisional patent previously filed on February 1, 2017; plus, additional data describing their mechanism of action and further supporting their claims. Inflammatory disorders, such as arthritis, asthma, eczema, psoriasis, Crohn's disease and Inflammatory Bowel Disease, represent a serious health burden in the US with over $200 billion spent annually. New cannabis-based therapies could significantly help both patients and society.\n\n\n \n \n\n \n\"Filing this nonprovisional patent signifies our passage to the next phase in the development of these cannabis-based anti-inflammatory compounds, which have the potential to alleviate patient suffering,\" explains Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. \"We look forward to commercializing the multiple disease-specific anti-inflammatory formulations in this patent application through different channels; including one potential pharmaceutical formulation that may be applied to an orphan indication and another with a nutraceutical-compliant formulation. GB Sciences also plans to develop a series of distinct anti-inflammatory formulations for sale in cannabis dispensaries. Development through different regulatory pathways and sales channels allows us to get some of these therapies to patients quicker and to implement a diversified sales strategy.\"\n\n\"GB Sciences is committed to developing products that improve peoples' lives and new anti...